Molecules hold promise in treating macular degeneration
Acucela and Sirion Therapeutics are conducting clinical trials of compounds designed to slow the progression of macular degeneration. The molecules delay the buildup of toxic byproducts that appear to cause the disease by reducing sensitivity of the eyes to light.
MIT Technology Review | 11/02
This story published in BIO SmartBrief on 11/02/2009
More from SmartBrief:
Study: StemCells therapy slows progression of macular degeneration
Monday, October 26, 2009
Vaccine triggers body to attack protein linked to colon cancer
Monday, July 27, 2009
CMS to reverse reimbursement policy that de-emphasized Avastin
Thursday, October 29, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|